UroGen Pharma (URGN) Equity Average: 2016-2025
Historic Equity Average for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to -$104.4 million.
- UroGen Pharma's Equity Average fell 473.97% to -$104.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$104.4 million, marking a year-over-year decrease of 473.97%. This contributed to the annual value of -$37.0 million for FY2024, which is 52.12% up from last year.
- According to the latest figures from Q3 2025, UroGen Pharma's Equity Average is -$104.4 million, which was down 49.31% from -$69.9 million recorded in Q2 2025.
- UroGen Pharma's 5-year Equity Average high stood at $86.4 million for Q1 2021, and its period low was -$127.5 million during Q2 2023.
- Over the past 3 years, UroGen Pharma's median Equity Average value was -$53.6 million (recorded in 2023), while the average stood at -$54.3 million.
- In the last 5 years, UroGen Pharma's Equity Average slumped by 2,277.50% in 2023 and then soared by 130.94% in 2024.
- Quarterly analysis of 5 years shows UroGen Pharma's Equity Average stood at $20.0 million in 2021, then tumbled by 482.10% to -$76.3 million in 2022, then grew by 29.77% to -$53.6 million in 2023, then spiked by 115.59% to $8.4 million in 2024, then slumped by 473.97% to -$104.4 million in 2025.
- Its Equity Average stands at -$104.4 million for Q3 2025, versus -$69.9 million for Q2 2025 and -$27.6 million for Q1 2025.